Company profile
Nuo Therapeutics, Inc.
OTC: AURX · Healthcare · Biotechnology
#744 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
48DFH 38DQ 53GM 70SS 43
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ filing timeliness, balance-sheet leverage
Methodology →Revenue TTM
$4.1M
Rev growth YoY (TTM)
+155.8%
Net income (FY)
-$2.5M
Employees
10
as of 2026-08-19
Market cap
$48.4M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.3M$3.3M2025
Net income-$2.5M-$2.5M2025
Operating income-$2.5M-$2.5M2025
Total assets$1.8M$1.8M2025
Liabilities$2.8M$2.8M2025
Equity-$956.6k-$956.6k2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product93%
License7%
By geography
Not disclosed.
The read
What is Nuo Therapeutics, Inc.’s revenue?
Nuo Therapeutics, Inc. booked $3.3M in FY2025 revenue, growing 143% year over year — faster than most Healthcare companies we track, at a -75.8% net margin.
Peers · Healthcare
Telescope Innovations Corp.——Caliber Imaging & Diagnostics, Inc.——United American Healthcare Corporation——ADM Tronics Unlimited, Inc.——American Medical Technologies Inc.——TransCanna Holdings Inc.——Neighbors
Harris →Key facts
CEODavid E. Jorden
SectorHealthcare
IndustryBiotechnology
HeadquartersHouston, TX
ExchangeOTC: AURX
Employees10
IPO date2017-10-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.